LYCOS RETRIEVER 
Spectrum
built 651 days ago
"The acceptance by the FDA of the ISO-Vorin NDA amendment represents an important milestone for Spectrum as it provides validation of our risk-reduced business model," said Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals. "ISO-Vorin represents one of eleven promising drugs in our pipeline that have the potential to be effective therapeutic agents."
Source:
MORE ABOUT
Spectrum Pharmaceuticals